CN Patent

CN121218989A — 使用伊潘立酮的治疗方法

Assigned to Vanda Pharmaceuticals Inc · Expires 2025-12-26 · 0y expired

What this patent protects

本文描述了一种使用伊潘立酮或其活性代谢物治疗需要这类治疗的患者的改进方法，其中，所述患者具有痛风史或者携带与伊潘立酮诱导的血清尿酸浓度升高相关的基因变体。所述改进方法包括监测患者的血清尿酸水平；当患者的血清尿酸水平超过参考水平时，开始降尿酸治疗或增加其剂量。

USPTO Abstract

本文描述了一种使用伊潘立酮或其活性代谢物治疗需要这类治疗的患者的改进方法，其中，所述患者具有痛风史或者携带与伊潘立酮诱导的血清尿酸浓度升高相关的基因变体。所述改进方法包括监测患者的血清尿酸水平；当患者的血清尿酸水平超过参考水平时，开始降尿酸治疗或增加其剂量。

Drugs covered by this patent

Patent Metadata

Patent number
CN121218989A
Jurisdiction
CN
Classification
—
Expires
2025-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.